PureTech Health

PRTCPre-clinical

PureHealth Health is a biotherapeutics company with a proven track record of translating scientific innovation into clinical and commercial value. It employs a distinctive operational model, acting as a biotech 'studio' that conceives, founds, and advances new companies around specific scientific programs. This approach has generated 29 therapeutic candidates, including three that have progressed from inception at PureTech to FDA approval. The company's strategy focuses on unlocking the potential of validated biology by improving efficacy, enabling oral delivery, or enhancing tolerability.

Market Cap

$384.2M

Focus

AntibodiesBiologicsSmall Molecules

PRTC · Stock Price

USD 15.8912.33 (-43.69%)

Historical price data

AI Company Overview

Technology Platform

A biotech 'studio' model focused on unlocking validated biology via improved tolerability, oral delivery (e.g., Glyph™ lymphatic targeting platform), and efficacy enhancement to create new medicines.

Opportunities

Major growth opportunities include the successful late-stage development and commercialization of LYT-100 in the large IPF market, the expansion of the Glyph platform into non-opioid pain, and leveraging the oral delivery expertise (Entrega) to tap into the massive demand for next-generation GLP-1 therapies.

The continued value inflection of its Founded Entity portfolio provides additional upside.

Risk Factors

Key risks include clinical trial failures for lead assets, the complexity and capital intensity of managing a multi-entity portfolio, potential future shareholder dilution, and dependence on the commercial success of partnered or spun-out entities like Karuna (Cobenfy) which it does not control.

Competitive Landscape

PureTech competes across multiple therapeutic areas: in IPF against Roche/Genentech and Boehringer Ingelheim; in schizophrenia against established antipsychotic makers; and in platform tech against other drug delivery companies. Its primary differentiation is its 'studio' model, which allows it to source and de-risk novel science early and create focused entities, giving it a unique pipeline breadth and a proven track record of regulatory success.

Publications

Patents